But Most People Who Have Diabetes Have Nothing More Than Minor Eye Disorders.

Sometimes, deposits of cholesterol or other fats from the blood may leak into the retina. The fluid makes the macula swell, blurring vision. The new vessels are also often accompanied by scar tissue that may cause the retina to wrinkle or detach. In this form, the blood vessels are so damaged they close off. Retinal detachment can cause permanent blindness if left untreated. However, they are weak and often burst, causing bleeding in the eye. If you are not able to keep your blood sugar levels in a target range, it can cause damage to your blood vessels. http://www.gahawisri.com/eastonwilsonblog/2016/11/04/some-growing-challenges-in-logical-glaucoma-secrets/You can also learn ways to manage your diabetic retinopathy. This results in blurred vision or poor night vision. Anti-veg drugs are injected into the vitreous gel to block a protein called vascular endothelial growth factor VEGF, which can stimulate abnormal blood vessels to grow and leak fluid. The small laser scars that result will reduce abnormal blood vessel growth and help bond the retina to the back of your eye, thus preventing retinal detachment.

When the macula swells with fluid, a condition called macula enema, vision blurs and can be lost entirely. Leitgeb A, et al. But most people who have diabetes have nothing more than minor eye disorders. Solar retinopathy due to direct sunlight exposure. American Diabetes Association: wow.diabetes.BBorg National Diabetes Information clearing-house: wow.diabetes.niddk.nib.gov Prevent Blindness America: wow.prevent blindness.org Managing your diabetes may help slow diabetic retinopathy and other eye problems. Retinopathy means that disease has damaged the retina. no dataIn this way, the damaged vessels and abnormal new vessels are identified.  They are studying the molecular basis of diabetic retinopathy and they have discovered that there are resident populations of cells within the eye that can be manipulated in order to promote repair.

News Image Currently, the development of the Nova Oculus device is focused on securing the necessary international certifications that are required before various government-sanctioned regulatory approvals can be granted. Mass production of the device by the companys manufacturing partner is slated to begin in the spring of 2017. Company officials expect that once certification for the device from the International Organization of Standards is granted, regulatory approval in Canada is achieved, and CE Mark approval for the European market is given, gaining access to other international markets will follow. It is estimated that more than 26 million people in Britain, the EU, Japan and Australia are afflicted with AMD. As many as three-quarters of a million of those could be treated by the Nova Oculus device in the first year alone. After five years, that number could be as high as 3.75 million patients. According to the companys calculations, a potential market of that size could conservatively represent $245 million in revenue from treatments and equipment leases in the first year. After five years, that figure could be as high as $500 million. These figures do not include the numbers from Canada, the U.S., or elsewhere. About Nova Oculus: Nova Oculus Partners, LLC was formed to develop, manufacture, and lease to medical professionals an electrotherapeutic medical device to treat visual disease, providing a pulsed micro-current output delivered to the retina by way of a closed eyelid.

For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2016/11/prweb13820161.htm